Whole-joint magnetic resonance imaging to assess osteonecrosis in pediatric patients with acute lymphoblastic lymphoma.
acute lymphoblastic lymphoma
magnetic resonance imaging
osteonecrosis
pediatrics
whole joints
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
19
12
2019
revised:
04
03
2020
accepted:
25
03
2020
pubmed:
31
5
2020
medline:
8
9
2020
entrez:
31
5
2020
Statut:
ppublish
Résumé
Osteonecrosis is a debilitating complication in children and adolescents with acute lymphoblastic leukemia or acute lymphoblastic lymphoma (LLy). An objective screening test to identify patients at risk for symptomatic, extensive joint involvement will help manage osteonecrosis. We performed a prospective, longitudinal pilot study with whole-joint magnetic resonance imaging (MRI) of shoulders, elbows, hips, knees, ankles, and hindfeet to evaluate the incidence and timing of osteonecrosis involving multiple joints in 15 patients with LLy aged 9-21 years at diagnosis. Osteonecrosis affecting ≥30% of the epiphysis occurred in eight of 15 patients, with a high prevalence in hips (12 of 26 examined [46%]) and knees (10 of 26 [38%]) post reinduction I and in shoulders (seven of 20 [35%]) post reinduction II. Most osteonecrotic hips and knees with ≥30% epiphyseal involvement became symptomatic and/or underwent surgery (100% and 82%, respectively). All eight patients with ≥30% epiphyseal involvement had multijoint involvement. Seven of these patients had hip or knee osteonecrosis by the end of remission induction, and only these patients developed osteonecrosis that became symptomatic and/or underwent surgery in their hips, knees, shoulders, ankles, and/or feet; all of these joints were associated with epiphyseal abnormalities on post reinduction I imaging. MRI screening in adolescent patients with LLy revealed osteonecrosis in multiple joints. Initial screening with hip and knee MRI at the end of induction may identify susceptible patients who could benefit from referrals to subspecialties, more extensive follow-up imaging of other joints, and early medical and surgical interventions.
Sections du résumé
BACKGROUND
Osteonecrosis is a debilitating complication in children and adolescents with acute lymphoblastic leukemia or acute lymphoblastic lymphoma (LLy). An objective screening test to identify patients at risk for symptomatic, extensive joint involvement will help manage osteonecrosis.
METHODS
We performed a prospective, longitudinal pilot study with whole-joint magnetic resonance imaging (MRI) of shoulders, elbows, hips, knees, ankles, and hindfeet to evaluate the incidence and timing of osteonecrosis involving multiple joints in 15 patients with LLy aged 9-21 years at diagnosis.
RESULTS
Osteonecrosis affecting ≥30% of the epiphysis occurred in eight of 15 patients, with a high prevalence in hips (12 of 26 examined [46%]) and knees (10 of 26 [38%]) post reinduction I and in shoulders (seven of 20 [35%]) post reinduction II. Most osteonecrotic hips and knees with ≥30% epiphyseal involvement became symptomatic and/or underwent surgery (100% and 82%, respectively). All eight patients with ≥30% epiphyseal involvement had multijoint involvement. Seven of these patients had hip or knee osteonecrosis by the end of remission induction, and only these patients developed osteonecrosis that became symptomatic and/or underwent surgery in their hips, knees, shoulders, ankles, and/or feet; all of these joints were associated with epiphyseal abnormalities on post reinduction I imaging.
CONCLUSIONS
MRI screening in adolescent patients with LLy revealed osteonecrosis in multiple joints. Initial screening with hip and knee MRI at the end of induction may identify susceptible patients who could benefit from referrals to subspecialties, more extensive follow-up imaging of other joints, and early medical and surgical interventions.
Identifiants
pubmed: 32472969
doi: 10.1002/pbc.28336
pmc: PMC7391358
mid: NIHMS1611656
doi:
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28336Subventions
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NCI NIH HHS
ID : CA21765
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
J Pediatr Orthop. 2019 Feb;39(2):104-110
pubmed: 28452860
J Clin Oncol. 2007 Apr 20;25(12):1525-31
pubmed: 17442995
Blood. 2016 Feb 4;127(5):558-64
pubmed: 26590194
J Clin Oncol. 2015 Feb 20;33(6):610-5
pubmed: 25605853
Lancet Oncol. 2012 Sep;13(9):906-15
pubmed: 22901620
Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):483-5; discussion 486
pubmed: 18064641
J Clin Oncol. 2008 Apr 20;26(12):1932-9
pubmed: 18421047
Nat Rev Clin Oncol. 2019 Apr;16(4):227-240
pubmed: 30546053
Am J Pathol. 2013 Jul;183(1):19-25
pubmed: 23673001
Leuk Lymphoma. 2019 Jan;60(1):78-84
pubmed: 29718744
Blood Adv. 2017 Jun 13;1(14):981-994
pubmed: 29296741
Lancet Oncol. 2012 Sep;13(9):855-7
pubmed: 22901621
Blood. 2011 Feb 24;117(8):2340-7; quiz 2556
pubmed: 21148812
Blood. 2015 Oct 8;126(15):1770-6
pubmed: 26265699
Arch Orthop Trauma Surg. 2016 Feb;136(2):165-74
pubmed: 26667621
PLoS One. 2016 Mar 11;11(3):e0151433
pubmed: 26967741